In last trading session, Beam Therapeutics Inc (NASDAQ:BEAM) saw 2.09 million shares changing hands with its beta currently measuring 2.36. Company’s recent per share price level of $18.48 trading at $0.84 or 4.79% at ring of the bell on the day assigns it a market valuation of $1.85B. That closing price of BEAM’s stock is at a discount of -90.75% from its 52-week high price of $35.25 and is indicating a premium of 5.03% from its 52-week low price of $17.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.55 million shares which gives us an average trading volume of 1.76 million if we extend that period to 3-months.
For Beam Therapeutics Inc (BEAM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.39. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Upright in the green during last session for gaining 4.79%, in the last five days BEAM remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $18.48 price level, adding 19.55% to its value on the day. Beam Therapeutics Inc’s shares saw a change of -25.48% in year-to-date performance and have moved -15.65% in past 5-day. Beam Therapeutics Inc (NASDAQ:BEAM) showed a performance of -30.11% in past 30-days. Number of shares sold short was 12.16 million shares which calculate 5.31 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 38 to the stock, which implies a rise of 51.37% to its current value. Analysts have been projecting 25 as a low price target for the stock while placing it at a high target of 57. It follows that stock’s current price would drop -35.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.28% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -3.23% while estimates for its earnings growth in next 5 years are of -1.00%.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
Insiders are in possession of 1.21% of company’s total shares while institution are holding 79.10 percent of that, with stock having share float percentage of 80.07%. Investors also watch the number of corporate investors in a company very closely, which is 79.10% institutions for Beam Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BEAM for having 7.9 million shares of worth $185.11 million. And as of 2024-06-30, it was holding 9.6701 of the company’s outstanding shares.
The second largest institutional holder is FARALLON CAPITAL MANAGEMENT LLC, which was holding about 7.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6135 of outstanding shares, having a total worth of $185.4 million.
On the other hand, ARK ETF Trust-ARK Innovation ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 4.97 shares of worth $91.91 million or 4.98% of the total outstanding shares. The later fund manager was in possession of 2.31 shares on Dec 31, 2024 , making its stake of worth around $42.69 million in the company or a holder of 2.31% of company’s stock.
